Mid-Morning Market Update: Markets Edge Higher; Best Buy Earnings Top Estimates
Following the market opening Tuesday, the Dow traded up 0.11% to 35,374.12 while the NASDAQ rose 0.43% to 15,006.17. The S&P also rose, gaining 0.22% to 4,489.23.
Benzinga Pro’s Top 4 Stocks To Watch For Tuesday, Aug. 24, 2021: NVDA, SPLK, LOOP, BPTH
Today's 4 Stock Ideas:
NVIDIA (NVDA) - Shares have rallied over the all-important $200 level over the last few trading sessions. The stock was up about 17% since rebounding off the $190 level last
Why Bio-Path Shares Are Moving Higher In Premarket Tuesday?
The FDA has signed off Bio-Path Holdings Inc’s (NASDAQ:BPTH) Investigational New Drug (IND) application for BP1002 in refractory/relapsed acute myeloid leukemia…
The Daily Biotech Pulse: Cara’s Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 23)
Bio-Path Holdings Announces FDA Clearance Of Investigational New Drug Application For BP1002 In Refractory/Relapsed Acute Myeloid Leukemia Patients
Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today
The Daily Biotech Pulse: Moderna’s Vaccine Produces Durable Response Against Variants, FDA Approves Jazz’s Sleep Disorder Drug, Dermata IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 12)
Bio-Path Holdings Q2 EPS $(0.26) Beats $(0.39) Estimate
Bio-Path Holdings (NASDAQ:BPTH) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.39) by 33.33 percent. This is a 52.73 percent increase over losses of $(0.55) per share from
Earnings Scheduled For August 13, 2021
Companies Reporting Before The Bell
• Jaguar Health (NASDAQ:JAGX) is expected to report quarterly loss at $0.03 per share on revenue of $7.28 million.
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the week.